High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC …
R Willemze, S Suciu, G Meloni, B Labar… - Journal of clinical …, 2014 - ascopubs.org
Purpose Cytarabine plays a pivotal role in the treatment of patients with acute myeloid
leukemia (AML). Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 …
leukemia (AML). Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 …
Intermediate-risk acute myeloid leukemia therapy: current and future
K Döhner, P Paschka - Hematology 2014, the American Society …, 2014 - ashpublications.org
In recent years, research in molecular genetics has been instrumental in deciphering the
molecular heterogeneity of acute myeloid leukemia (AML), in particular the subset of …
molecular heterogeneity of acute myeloid leukemia (AML), in particular the subset of …
High number of additional genetic lesions in acute myeloid leukemia with t (8; 21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome
MT Krauth, C Eder, T Alpermann, U Bacher… - Leukemia, 2014 - nature.com
Abstract t (8; 21)/RUNX1-RUNX1T1-positive acute myeloid leukemia (AML) is prognostically
favorable; however, outcome is heterogeneous. We analyzed 139 patients with t (8; …
favorable; however, outcome is heterogeneous. We analyzed 139 patients with t (8; …
[HTML][HTML] Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions
AS Kanate, MC Pasquini, PN Hari… - World journal of stem …, 2014 - ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) represents a heterogeneous group of high-grade myeloid
neoplasms of the elderly with variable outcomes. Though remission-induction is an …
neoplasms of the elderly with variable outcomes. Though remission-induction is an …
Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia
Conventionally, acute myeloid leukemia (AML) patients are categorized into good-,
intermediate-and poor-risk groups according to cytogenetic changes. However, patients with …
intermediate-and poor-risk groups according to cytogenetic changes. However, patients with …
Outcome of patients with abnl (17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
JM Middeke, M Fang, JJ Cornelissen… - Blood, The Journal …, 2014 - ashpublications.org
Patients with acute myeloid leukemia (AML) and abnormalities of chromosome 17p (abnl
(17p)) are at high-risk of treatment failure. Poor outcomes have been reported with …
(17p)) are at high-risk of treatment failure. Poor outcomes have been reported with …
Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML
C Anthias, FL Dignan, R Morilla, A Morilla… - Bone marrow …, 2014 - nature.com
The presence of minimal residual disease (MRD) by multiparametric flow cytometry (MFC)
has been associated with adverse outcomes in AML patients treated with chemotherapy …
has been associated with adverse outcomes in AML patients treated with chemotherapy …
[HTML][HTML] Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after …
M Eefting, PA Von dem Borne, LC De Wreede… - …, 2014 - ncbi.nlm.nih.gov
The prognosis of patients with relapsed acute myeloid leukemia after allogeneic
transplantation is poor. We hypothesized that initial disease control by effective …
transplantation is poor. We hypothesized that initial disease control by effective …
Second primary malignancies in adult acute myeloid leukemia-A US population-based study
KB Ghimire, BK Shah - Anticancer Research, 2014 - ar.iiarjournals.org
Background: Acute myeloid leukemia (AML) is the most common type of acute leukemia in
adults. Long-term survivors from AML may be at higher risk of second primary malignancies …
adults. Long-term survivors from AML may be at higher risk of second primary malignancies …
[HTML][HTML] Mobilization-driven postconsolidation therapy in elderly patients with acute myeloid leukemia: feasibility and efficacy of autologous stem cell transplantation …
We prospectively evaluated 2 postconsolidation strategies, administered according to the
mobilization outcome, in 72 acute myeloid leukemia (AML) fit elderly patients, achieving …
mobilization outcome, in 72 acute myeloid leukemia (AML) fit elderly patients, achieving …